The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

There's no telling where the call will come from, or when. But Randy Cron, M.D., Ph.D., professor of pediatrics and medicine at UAB, knows to expect them. "Not a week goes by when I don't get a call ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract ...

As the first clinical data become available on treating coronavirus patients with the cells, scientists are equivocal about the rationale for the intervention. The immunotherapy induces a form of cell ...

As CAR T-cell therapy becomes more common in oncology, predicting the patients who may experience the life-threatening complication called cytokine release syndrome (CRS) is becoming more important.

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Immunologists are proposing a possible molecular mechanism that causes massive release of proinflammatory cytokines, or a cytokine storm, leading to the acute respiratory distress syndrome (ARDS) in ...

Cytokine release syndrome can limit aggressive RRMM treatment strategies. Jeffrey Matous, MD: We’re going to talk about hurdles giving these treatments. First, let’s talk about the timing of CRS ...